You can download the publications of the team here:

Year Title PDF
2023 Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma
2023 Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia
2023 EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
2023 Var∣Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data
2022 LAIR1, an ITIM-Containing Receptor Involved in Immune Disorders and in Hematological Neoplasms
2022 The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
2022 PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma
2022 Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma
2022 Comprehensive Characterization of the Epigenetic Landscape in Multiple Myeloma
2021 Targeting the Methyltransferase SETD8 Impairs Tumor Cell Survival and Overcomes Drug Resistance Independently of p53 Status in Multiple Myeloma
2021 RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
2021 RNA-sequencing Data-Driven Dissection of Human plasma cell Differentiation reveals new potential Transcription Regulators
2021 Multi-omics Tumor Profiling Technologies to develop Precision Medicine in Multiple Myeloma
2021 The Origin of Preplasmablastic Cells
2020 Role of Polycomb Complexes in Normal and Malignant Plasma Cells
2020 DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets
2020 Kinome expression profiling to target new therapeutic avenues in multiple myeloma
2019 CD38 antibodies in multiple myeloma
2019 EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation
2019 Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
2019 Phenotype Characterization of Diffuse Large B cell Lymphoma Cells and Prognostic Impact
2019 Treatment may be harmful : mechanisms/preduction/prevention of drug-induced DNA damage and repair in multiple myeloma
2019 Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
2018 BrdU incorporation in multiparameter flow cytometry : A new cell cycle assessment approach in multiple myeloma
2018 PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
2018 DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
2017 Combined inhibition of two bad prognosis genes: Chk1 and Wee1 as a new therapeutic strategy for Multiple Myeloma [Abstract]
2017 Combined inhibition of two bad prognosis genes: Chk1 and Wee1 as a new therapeutic strategy for Multiple Myeloma [Poster]
2017 CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
2017 An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients
who may benefit from epigenetic therapy
2017 Automated and Simplified Identification of Normal and Abnormal Plasma Cells in Multiple Myeloma by Flow Cytometry
2017 Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell
2017 RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
2017 Automated and Simplified Identification of Normal and Abnormal Plasma Cells in Multiple Myeloma by Flow Cytometry
2017 Hypoxia favors the generation of human plasma cells
2016 EZH2 in normal hematopoiesis and hematological malignancies
2016 Differential effects of lenalidomide during plasma cell differentiation
2016 Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy
2016 Chetomin, targeting HIF-1a/p300 complex, exhibits antitumour activity in multiple myeloma
2015 Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma
2015 GenomicScape : AnEasy-to-Use Web Tool for Gene Expression Data Analysis. Application
to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells
2014 Drug metabolism and clearance system in tumor cells of patients with Multiple Myeloma
2014 DNA repair in diffuse large B-cell lymphoma: a molecular portrait
2013 Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma
2013 Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
2012 Gene expression-based risk score in diffuse large B-cell lymphoma
2012 Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients
2012 Development of gene expression based score to predict sensitivity of multiple myeloma cells to DNA methylation
2011 Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation
2011 A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
2009 An in vitro model of differentiation of memory B cells into plasma blasts and plasma cells including detailed phenotypic and molecular characterization

The Patents of the Team:

Year Title
2019 Methods for the in vitro determination of the outcome and for the treatment of individuals having multiple myeloma. Hassen W, Kassambara A, Moreaux J.
PCT/ EP2019052992; WO2019154905A1.
2018 Prognosis method of multiple myeloma. De Boussac H, Kassambara A and Moreaux J.
PCT/EP2018079749; WO2019086478A1.
2017 Method for the in vitro prognosis of individuels having multiple myeloma and method for the treatment thereof. Herviou L, Kassambara A, Cavalli G, Moreaux J.
PCT/EP2017/077887; WO2018/083086A1.
2017 Residual disease detection in multiple myeloma. Requirand G, Klein B, Reme T, Moreaux J and al.
PCT/EP2017/062307 ; WO2017198879A1. Patent FR1654514
2017 Methods using blm as a marker of multiple myeloma. Moreaux J, Sapede E, Pasero P, Constantinou A.
PCT/EP2017/064020; WO2017211983A1. Patent EP16305682,
2017 Methods and pharmaceutical compositions for the treatment of multiple myeloma. Moreaux J, Julien E, Izard F, Grimaud C, Herviou L.
PCT/EP2017/053435; WO2017140743A1 Patent EP16305176
2016 Method for the in vitro prognosis of individuals having Multiple Myeloma and method for the treatment thereof. Cavalli G, Kassambara A, Herviou L. Moreaux J.
Patent EP16306436.3,
2016 Method for the prognosis of multiple myeloma. Aleterre E, Moreaux J.
Patent EP16305651
2014 Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma. Moreaux J, Bret C, Cartron G, Constantinou A, Pasero P. PCT/EP2015/067174
Patent EP14306201
2014 Method for predicting DNMTi/HDACi combination treatment response in Multiple Myeloma. Moreaux J, Klein B. EP2015/055992
Patent EP14305404,
2012 Method for predicting HDACi treatment response in Multiple Myeloma. Moreaux J, Klein B.
WO2014056928 Patent EP12306225.9,
2012 Method for predicting multiple myeloma treatment response. Moreaux J, Klein B.
WO2014044848 Patent EP12306141.8,
2010 Classification, diagnosis and prognosis of multiple myeloma. Moreaux J, Pellat-Deceunynck C, Klein B.
WO2012022634 Patent n° 10305892

On November 5, 2018   /   Publications